{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:40:10Z","timestamp":1756291210876,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00401422"],"award-info":[{"award-number":["RS-2024-00401422"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.dmd.2025.100115","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:07:25Z","timestamp":1750878445000},"page":"100115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxylation near the epoxyketone of carfilzomib confers protection from microsomal epoxide hydrolase-mediated metabolism"],"prefix":"10.1016","volume":"53","author":[{"given":"Seongsoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-7591","authenticated-orcid":false,"given":"Jun Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-2688","authenticated-orcid":false,"given":"Chan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-2391","authenticated-orcid":false,"given":"Jiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Bo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7676","authenticated-orcid":false,"given":"Hyunyoung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-869X","authenticated-orcid":false,"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dmd.2025.100115_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"6299","key":"10.1016\/j.dmd.2025.100115_bib2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aaf8993","article-title":"The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design","volume":"353","author":"Schrader","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-014-0111-8","article-title":"Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models","volume":"33","author":"Baker","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.dmd.2025.100115_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100115_bib6","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"22","key":"10.1016\/j.dmd.2025.100115_bib7","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.dmd.2025.100115_bib8","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.dmd.2025.100115_bib9","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.drudis.2018.06.010","article-title":"Importance of target-mediated drug disposition for small molecules","volume":"23","author":"Smith","year":"2018","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.dmd.2025.100115_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-015-9445-x","article-title":"Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice","volume":"42","author":"Zhang","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12920-018-0354-x","article-title":"HLA and proteasome expression body map","volume":"11","author":"Boegel","year":"2018","journal-title":"BMC Med Genomics"},{"issue":"6","key":"10.1016\/j.dmd.2025.100115_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/A:1012414806166","article-title":"Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours","volume":"33","author":"Coller","year":"2001","journal-title":"Histochem J"},{"key":"10.1016\/j.dmd.2025.100115_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-017-0086-1","article-title":"Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study","volume":"6","author":"Brown","year":"2017","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"10.1016\/j.dmd.2025.100115_bib14","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.dmd.2025.100115_bib15","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1021\/acs.jmedchem.8b01943","article-title":"Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib","volume":"62","author":"Lee","year":"2019","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.dmd.2025.100115_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.dmd.2025.100115_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112206","article-title":"Development of potent inhibitors of the human microsomal epoxide hydrolase","volume":"193","author":"Barnych","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"Pt 8","key":"10.1016\/j.dmd.2025.100115_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: a tool for high-throughput crystallography of protein-ligand complexes","volume":"60","author":"Schuttelkopf","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.dmd.2025.100115_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68445","article-title":"EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence","volume":"10","author":"Gautheron","year":"2021","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.dmd.2025.100115_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/bdd.2000","article-title":"In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats","volume":"37","author":"Parrish","year":"2016","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100115_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/dmd.117.075226","article-title":"In vitro metabolism of oprozomib, an oral proteasome inhibitor: role of epoxide hydrolases and cytochrome P450s","volume":"45","author":"Wang","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2025.100115_bib23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/00498254.2016.1151088","article-title":"Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition","volume":"46","author":"Rosa","year":"2016","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2025.100115_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100086","article-title":"Protocol for primary mouse hepatocyte isolation","volume":"1","author":"Charni-Natan","year":"2020","journal-title":"STAR Protoc"},{"issue":"2","key":"10.1016\/j.dmd.2025.100115_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116805","article-title":"In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products","volume":"10","author":"Liao","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1042\/bj2010189","article-title":"L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L","volume":"201","author":"Barrett","year":"1982","journal-title":"Biochem J"},{"key":"10.1016\/j.dmd.2025.100115_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jpba.2017.08.048","article-title":"Quantitative determination of carfilzomib in mouse plasma by liquid chromatography\u2013tandem mass spectrometry and its application to a pharmacokinetic study","volume":"146","author":"Min","year":"2017","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.dmd.2025.100115_bib28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/prot.25251","article-title":"Structural insights into human microsomal epoxide hydrolase by combined homology modeling, molecular dynamics simulations, and molecular docking calculations","volume":"85","author":"Saenz-Mendez","year":"2017","journal-title":"Proteins"},{"issue":"3","key":"10.1016\/j.dmd.2025.100115_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/hmg\/3.3.421","article-title":"Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants","volume":"3","author":"Hassett","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.dmd.2025.100115_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.taap.2008.02.023","article-title":"Microsomal epoxide hydrolase (EPHX1), slow (exon 3, 113His) and fast (exon 4, 139Arg) alleles confer susceptibility to squamous cell esophageal cancer","volume":"230","author":"Jain","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100115_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/0049825021000061615","article-title":"Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects","volume":"33","author":"Maekawa","year":"2003","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.dmd.2025.100115_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2025.100115_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0163-7258(96)00184-2","article-title":"Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data","volume":"73","author":"Iwatsubo","year":"1997","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2025.100115_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/0091270009333209","article-title":"Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches","volume":"49","author":"Hosea","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/clpt.1989.110","article-title":"Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro\/in vivo correlation","volume":"46","author":"Kerr","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2025.100115_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/clpt.1983.8","article-title":"Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide","volume":"33","author":"Tomson","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.dmd.2025.100115_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111595","article-title":"Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100115_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0005-2736(77)90007-4","article-title":"The effects of N-ethylmaleimide on active amino acid transport in Escherichia coli","volume":"464","author":"Janick","year":"1977","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.dmd.2025.100115_bib39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1042\/bj0910589","article-title":"Reactions of N-ethylmaleimide with peptides and amino acids","volume":"91","author":"Smyth","year":"1964","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.dmd.2025.100115_bib40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/ijms22030997","article-title":"Mechanisms applied by protein inhibitors to inhibit cysteine proteases","volume":"22","author":"Tu\u0161ar","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.dmd.2025.100115_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0968-0004(91)90058-4","article-title":"Cell-penetrating inhibitors of calpain","volume":"16","author":"Mehdi","year":"1991","journal-title":"Trends Biochem Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:12:49Z","timestamp":1756289569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562509124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S009095562509124X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100115","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxylation near the epoxyketone of carfilzomib confers protection from microsomal epoxide hydrolase-mediated metabolism","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100115"}}